Completed PHASE1 INTERVENTIONAL 6-arm NCT00495872

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Sponsor: M.D. Anderson Cancer Center

Interventions Dasatinib Erlotinib Lapatinib Lenalidomide Sorafenib Sunitinib Valproic Acid

Updated 5 times since 2017 Last updated: Oct 16, 2012 Started: Jun 30, 2007 Primary completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00495872, this PHASE1 trial focuses on Solid Tumors and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States